Specifically, Boston leads the way in embracing new research models (for example, Research at the Broad Institute of Harvard and MIT) and, in building a new research culture that has strong roots in academia and the pharma sector. A recent contribution of US$650 million as the philanthropic donation to Broad is the true testimony. It […]
Pharma Industry
Penicillin Allergies: Breaking the Myth
Yes, penicillin allergies are real. Common symptoms include diarrhea and nausea and in rare cases, anaphylactic shock. You might have had an abnormal reaction to a dose of penicillin when you were younger. You may be wary about taking any further penicillin-based shots. But chances are, your immune system has already outgrown it, or you […]
Things you need to know about Indian Pharma industry shifting paradigm
Indian Pharma industry is currently undergoing unprecedented changes. There is huge growth in Indian Pharma because the industry has received product patents. This has been instrumental in the industry’s huge achievement as a international exporter of superlative generic drugs. The new patent regime had led to the return of the pharmaceutical multinationals. India is evolving […]
Continue reading Things you need to know about Indian Pharma industry shifting paradigm
Personalised Medicines for Patients Well Being
Many mergers and acquisitions, partnerships and collaborations still offer opportunities for growth for the Pharma industry. But others think that personalised medicine if used cleverly will take the Pharma industry on the right path. Usage of well-customised therapies to treat diseases based on the patient genetic makeup can offer companies alternative possibilities for growth in […]
Continue reading Personalised Medicines for Patients Well Being
The Lasting Advantage
Why are some firms more competitive than others? This is the central question of my research in the field of strategic management. Decades of research, in both the life sciences and other industries, have converged to suggest there are perhaps three overarching reasons. The first is the most obvious: what academics call the ‘Resource-Based View […]
Next Generation Pharmacovigilance
In an environment where development costs have increased exponentially while filings and launches have dropped drastically, the pharmaceutical industry and drug regulators face numerous challenges in Pharmacovigilance (PV), patient safety and in addressing areas of unmet medical needs. This combination of issues not only adds unsustainable access restrictions and costs in the long term, but […]
Breaking Down Borders
If you had run into Mark Engel, CEO and founder of Excel PharmaStudies, at the recent 2008 China Pharmaceutical R&D Summit at Shanghai, you would realise that even the young biotech industry in Asia is not immune to the rapid globalisation of drug discovery and development. Excel, a leading CRO, was started by a western […]
Metabolic Biomarker and Target Discovery in Obesity-Associated Comorbidities
Millions of adults are diagnosed as obese each year worldwide. Many of these people suffer from a disorder known as metabolic syndrome, which includes symptoms such as hypertension and elevated blood cholesterol. They are also at risk of developing additional diseases, such as heart disease and diabetes mellitus. Obesity may, in fact, be a major […]
Continue reading Metabolic Biomarker and Target Discovery in Obesity-Associated Comorbidities
Outsourcing preclinical and clinical R&D to China
China has emerged from the shadows of isolation to become a world economic power with a staggering growth rate (8% per annum for the past five years) that will soon eclipse the likes of France and England. Low-cost manufacturing and the availability of inexpensive and abundant labour have fuelled this growth. However, in order to […]
Continue reading Outsourcing preclinical and clinical R&D to China
The Arab Drug Industry
In response to the 21st century challenges to the health sector, WHO established an important global commission on Macroeconomics and Health. One of the important conclusions of the commission report indicated that by the year 2015, the world could save up to 10.5 million lives every year by scaling up access to existing health interventions […]